Uploaded April 2021 | Updated November 2026, 5 days ago
This is video of a SARS-CoV-2 spike protein under siege.
The little blobs buzzing around it are called lectins, and they could be the secret weapon in a new defence against COVID-19, new research from the Life Sciences Institute at the University of British Columbia has found.
Most COVID-19 drugs currently in clinical trials are designed to block receptor sites on our cells -- the little doors on the surface of our cells that the SARS-CoV-2 spike protein breaches to gain access.
But this treatment would be different, targeting the spike protein itself. The protein hides from our immune system by covering itself with sugar molecules called glycans. These glycans are a disguise that helps the virus get in the door.
What if, instead of trying to block the door, you gummed up the key instead? That's what Dr. Josef Penninger, director of the Life Sciences Institute at UBC, and his international team of researchers set out to do.
They developed the largest lectin library in the world to find two lectins that are particularly good at binding to glycans on the SARS-CoV-2 spike protein. These lectins are the gum on the key, and could be the starting point for a lectin-based drug to combat COVID-19.
The best part? The glycan sites that the spike protein uses for its disguise show up in all circulating variants of the SARS-CoV-2 virus. "This could be its Achilles' heel," says Dr. Penninger.
Not only have the researchers learned how these lectins bind to the spike protein, they've recorded it happening.
Video recorded by: Daniel Canena and Peter Hinterdorfer (Institute of Biophysics, Johannes Kepler University, Linz, Austria / @Jkulinz on Twitter)
The researchers' work is available as a pre-print at bioRxiv: biorxiv.org/content/10.1101/2021.04.01.438087v1
Read more: news.ubc.ca/2021/04/30/potential-achilles-heel-of-sars-cov-2-virus-captured-on-video
This is video of a SARS-CoV-2 spike protein under siege.
The little blobs buzzing around it are called lectins, and they could be the secret weapon in a new defence against COVID-19, new research from the Life Sciences Institute at the University of British Columbia has found.
Most COVID-19 drugs currently in clinical trials are designed to block receptor sites on our cells -- the little doors on the surface of our cells that the SARS-CoV-2 spike protein breaches to gain access.
But this treatment would be different, targeting the spike protein itself. The protein hides from our immune system by covering itself with sugar molecules called glycans. These glycans are a disguise that helps the virus get in the door.
What if, instead of trying to block the door, you gummed up the key instead? That's what Dr. Josef Penninger, director of the Life Sciences Institute at UBC, and his international team of researchers set out to do.
They developed the largest lectin library in the world to find two lectins that are particularly good at binding to glycans on the SARS-CoV-2 spike protein. These lectins are the gum on the key, and could be the starting point for a lectin-based drug to combat COVID-19.
The best part? The glycan sites that the spike protein uses for its disguise show up in all circulating variants of the SARS-CoV-2 virus. "This could be its Achilles' heel," says Dr. Penninger.
Not only have the researchers learned how these lectins bind to the spike protein, they've recorded it happening.
Video recorded by: Daniel Canena and Peter Hinterdorfer (Institute of Biophysics, Johannes Kepler University, Linz, Austria / @Jkulinz on Twitter)
The researchers' work is available as a pre-print at bioRxiv: biorxiv.org/content/10.1101/2021.04.01.438087v1
Read more: news.ubc.ca/2021/04/30/potential-achilles-heel-of-sars-cov-2-virus-captured-on-video










